Over the last 7 days, the United States market has dropped by 1.5%, but it remains up 16% over the past year with earnings forecasted to grow by 17% annually. While 'penny stocks' might seem like a term from a bygone era, they still highlight smaller or newer companies that can offer significant value when backed by strong financials. In this context, we've identified three penny stocks that combine balance sheet strength with potential for growth, offering investors an opportunity to discover hidden value in quality companies.

Below we spotlight a couple of our favorites from our exclusive screener.

Scienjoy Holding (SJ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Scienjoy Holding Corporation operates mobile live streaming platforms in the People’s Republic of China, with a market cap of $39.07 million.

Operations: The company generates revenue from its Internet Telephone segment, totaling CN¥1.22 billion.

Market Cap: $39.07M

Scienjoy Holding Corporation, with a market cap of US$39.07 million, operates in the mobile live streaming sector in China. Despite being unprofitable and experiencing significant earnings decline over the past five years, it reported first-quarter revenue of CN¥282.62 million and net income of CN¥8.88 million, marking a turnaround from a prior net loss. The company is debt-free with short-term assets exceeding both its short- and long-term liabilities significantly. However, its share price has been highly volatile recently, compounded by substantial insider selling over the past three months.

Telos (TLS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Telos Corporation, along with its subsidiaries, offers cyber, cloud, and enterprise security solutions both in the United States and internationally, with a market cap of $346.41 million.

Operations: The company generates revenue through two primary segments: Secure Networks, contributing $12.18 million, and Security Solutions, which accounts for $169.75 million.

Market Cap: $346.41M

Telos Corporation, with a market cap of US$346.41 million, operates in the cybersecurity sector and has shown resilience despite challenges. The company is unprofitable but maintains a strong financial position with short-term assets of US$95.6 million exceeding both short- and long-term liabilities. Recent developments include securing contracts with the U.S. Air Force and expanding its aviation channeling services across Hawaii's airports, highlighting its strategic partnerships and growth potential in security solutions. However, significant insider selling raises caution, alongside recent index reclassifications that reflect shifting market perceptions of its growth trajectory.

Outset Medical (OM)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Outset Medical, Inc. is a medical technology company focused on developing a hemodialysis system for use in the United States, with a market cap of $80.08 million.

Operations: The company generates revenue from its Surgical & Medical Equipment segment, totaling $117.59 million.

Market Cap: $80.08M

Outset Medical, Inc., with a market cap of US$80.08 million, is navigating challenges in the medical technology sector. The company reported first-quarter revenues of US$27.86 million and reduced its net loss compared to the previous year, though it remains unprofitable with a negative return on equity. Despite recent index exclusions that may impact investor perception, Outset Medical has secured a significant agreement with HCA Management Services worth approximately US$40 million for its Tablo Hemodialysis Systems. The company's strong short-term asset position and sufficient cash runway are positive financial indicators amidst its ongoing operational adjustments.

Taking Advantage

• Investigate our full lineup of 330 US Penny Stocks right here.
• Looking For Alternative Opportunities? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.